OncoAlert
@OncoAlert
Followers
39K
Following
119K
Media
4K
Statuses
107K
🌐 Worldwide Network of Oncology Professionals & Patient Advocates with the common goal of ending cancer, we are Oncology360 degrees 🌎 We are #OncoAlert 🚨
Worldwide
Joined March 2019
The OncoAlert WEEKLY RoundUp 🚨 .Covering the TOP of the week July 25-31, 2025 . 👉REGISTER at OR . Discussing: .✅Biomarkers🧬of response and resistance to immune checkpoint inhibitors in #BreastCancer by @LoiSher . ✅POETIC
0
12
33
RT @JankovicK: Alpelisib +Olaparib in platinum-resistant/refractory #HGSOC without BRCA mutations: . ❌ not improve PFS 🆚 chemo (3.6 🆚3.9 mo….
ascopubs.org
PURPOSEPatients with platinum-resistant/platinum-refractory high-grade serous ovarian cancer (HGSOC) without a BRCA mutation have poor prognosis and limited treatment options. We report efficacy and...
0
4
0
RT @DrYukselUrun: Biomarkers matter but not always how we expect!. 🧬In KEYNOTE-426, high T-cell-inflamed GEP predicted better outcomes with….
0
18
0
RT @MikeSerzanMD: 🚨 PAN MASS CHALLENGE WEEKEND HAS ARRIVED 🚨 . @PanMass is a fundraising 🚲 bike-a-thon started in 1980 that has raised over….
0
7
0
RT @BenWestphalen: 3/3 Here is the trial that led to the approval of zenocutuzumab - congrats to @AliSchram & co-workers. .
nejm.org
Neuregulin 1 (NRG1) fusions are recurrent oncogenic drivers found in multiple solid tumors. NRG1 binds to human epidermal growth factor receptor 3 (HER3), leading to heterodimerization with HER2 an...
0
1
0
RT @BenWestphalen: 1/3 Zenocutuzumab is @FDA approved for the treatment of NRG1-fusion-positive #cancers. Knowing the frequency & distribut….
nature.com
npj Precision Oncology - Comprehensive identification of NRG1 fusions in 25,203 patients with solid tumors
0
5
0
RT @FernandoOnco: Thank you for your presence and presentation here at our institution. We hope to see you soon and stay focused for longer….
0
0
0
RT @Abdallah81MD: 1/🇨🇳💥 Why I believe China is bypassing the U.S. in cellular therapy innovation (CAR-T, gene editing, etc.):.A thread 🧵👇….
0
6
0
RT @Lucarecco: European Clinical Trial Ecosystem report:.🌍 Global trials ↑ +38% in last 10 yrs.🇪🇺 EU share ↓ from 22% → 12% = ~60,000 fewer….
0
5
0
RT @gynoncjnls: Persistent opioid use among gynecologic oncology patients after surgery @SGO_org @IGCSociety @ESGO_society @ASCO @OncoAlert….
0
3
0
RT @ElisaAgostinett: Now out in @TheLancet the results of the randomized trial ASTER 70s. The addition of adjuvant CT to HT had no signific….
thelancet.com
The addition of adjuvant chemotherapy to hormonotherapy conferred no survival benefit in women aged 70 years and above with a GGI high-risk oestrogen receptor-positive HER2-negative breast cancer,...
0
9
0
RT @DarcyBurbage: Ck out this week’s @OncoAlert RoundUp from @weoncologists! .@oncologynursing @ISNCC @GPONursing.
0
2
0
RT @Erman_Akkus: 👩💻Telehealth in Oncology.@MASCC_JSCC . ✅@CancerCareMASCC endorsment of @ASCO recommendations. 👉 #….
0
18
0
RT @TresUramigas: 📢 KN426:.Tras 5 años de seguimiento, pembro + axitinib mantiene superioridad vs sunitinib en 1L ccRCC:.✅ OS: 47,2 vs 40,8….
0
7
0
RT @TresUramigas: 🔗Bmk estudiados más consistentes en #KN426:. 🟢TcellinfGEP → ↑ rta pembro+axi.🟢 Firma angiogénica (RNA) → ↑rta sunitinib….
0
4
0
RT @g_develasco: 🚨 When EV/pembro is not an option, what's the best first-line strategy for cisplatin-ineligible patients with advanced uro….
ascopubs.org
PURPOSEImmune checkpoint inhibitors combined with platinum-based chemotherapy is standard in patients with advanced/metastatic urothelial carcinoma (mUC). Cisplatin has immunomodulatory benefits...
0
14
0
RT @JournalCancer: Our #CancerAnnualReport reveals encouraging news about lung cancer: Incidence rates among men decreased in 2017–2021 for….
0
12
0
RT @GaiaGriguolo: When should we offer risk reducing surgery in women without BRCA1/BRCA2/PALB2 mut? .This data can help us better inform t….
0
5
0
RT @tompowles1: 2/2 Perhaps the most consistent biomarkers tested are the RNA angiogenic signature for sunitinib & the RNA activated T cel….
0
11
0
RT @tompowles1: 1/2: 5 year efficacy & biomarker data for axitinib/pembro in 1st line clear cell RCC. @OncoAlert Significant ⬆️ RR PFS & OS….
0
20
0
RT @JournalCancer: Thank you to our friends at @OncoAlert for highlighting the recent article by @DHE_Deakin researchers on the hidden cost….
acsjournals.onlinelibrary.wiley.com
Caring for people with cancer is a significant time commitment. The hidden economic burden of opportunity costs and the impact on quality of life in informal cancer care are substantial and often...
0
2
0